The ALKBH2 Knockout Jurkat Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the Jurkat T-cell line, in which the ALKBH2 gene has been disrupted to create a loss-of-function model. The polyclonal format represents a pool of edited cells, capturing heterogeneous gene-editing outcomes and avoiding the genetic bottlenecks of clonal isolation. This model is designed for precise dissection of ALKBH2’s roles in DNA repair and alkylation damage response.
The Jurkat parental line is an immortalized human T lymphocyte cell line derived from a T-cell acute lymphoblastic leukemia (T-ALL) patient. It is widely used for studying T-cell receptor signaling, leukemogenesis, and pharmacological sensitivity. Its robust growth in suspension and well-characterized DNA repair machinery make it an ideal host for exploring ALKBH2 function in a lymphoid malignancy context.
ALKBH2 is a DNA repair dioxygenase that directly reverses alkylation damage by demethylating 1-methyladenine and 3-methylcytosine in DNA. It is transcriptionally activated by p53 and NRF2 and physically interacts with PCNA, XRCC1, APE1, and DNA ligase III, linking direct reversal to the base excision repair pathway. Through cooperative action with PARP1 and DNA polymerase ??, ALKBH2 maintains genomic stability. Its knockout disrupts this network, leading to persistent alkylation lesions and heightened mutation rates.
In Jurkat cells, ALKBH2 deficiency confers marked sensitivity to alkylating agents such as temozolomide and methyl methanesulfonate, as shown by viability and DNA damage assays. Elevated ??H2AX foci and Comet tail moments indicate increased double-strand breaks and unrepaired adducts, underscoring ALKBH2’s role in replication fork protection. This sensitized phenotype enables research into chemoresistance mechanisms and synthetic interactions, particularly involving p53-directed apoptosis.
Key applications include Western blotting and RT-qPCR for DNA damage signaling profiling, alkylation adduct quantification, MTT and flow cytometry for viability and apoptosis, and Comet assay with ??H2AX immunofluorescence for direct DNA break assessment. These tools support studies of alkylating chemotherapy mechanisms, genotoxicity screening, and DNA repair pathway crosstalk. The polyclonal model provides population-level heterogeneity, enhancing translational relevance. For further technical specifications, please contact Ascent Research.
